Pharming Group Management
Management criteria checks 2/4
Pharming Group's CEO is Simon de Vries, appointed in Nov 2008, has a tenure of 16.17 years. total yearly compensation is $2.81M, comprised of 24% salary and 76% bonuses, including company stock and options. directly owns 2.13% of the company’s shares, worth €13.68M. The average tenure of the management team and the board of directors is 3.7 years and 3.9 years respectively.
Key information
Simon de Vries
Chief executive officer
US$2.8m
Total compensation
| CEO salary percentage | 24.0% |
| CEO tenure | 16.2yrs |
| CEO ownership | 2.1% |
| Management average tenure | 3.7yrs |
| Board average tenure | 3.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$18m |
| Jun 30 2024 | n/a | n/a | -US$13m |
| Mar 31 2024 | n/a | n/a | -US$11m |
| Dec 31 2023 | US$3m | US$673k | -US$11m |
| Sep 30 2023 | n/a | n/a | -US$22m |
| Jun 30 2023 | n/a | n/a | -US$16m |
| Mar 31 2023 | n/a | n/a | -US$2m |
| Dec 31 2022 | US$2m | US$636k | US$14m |
| Sep 30 2022 | n/a | n/a | US$30m |
| Jun 30 2022 | n/a | n/a | US$21m |
| Mar 31 2022 | n/a | n/a | US$11m |
| Dec 31 2021 | US$3m | US$681k | US$16m |
| Sep 30 2021 | n/a | n/a | US$22m |
| Jun 30 2021 | n/a | n/a | US$31m |
| Mar 31 2021 | n/a | n/a | US$37m |
| Dec 31 2020 | US$3m | US$614k | US$38m |
| Sep 30 2020 | n/a | n/a | US$44m |
| Jun 30 2020 | n/a | n/a | US$46m |
| Mar 31 2020 | n/a | n/a | US$42m |
| Jan 01 2020 | n/a | n/a | US$41m |
| Sep 30 2019 | n/a | n/a | US$38m |
| Jun 30 2019 | n/a | n/a | US$34m |
| Mar 31 2019 | n/a | n/a | US$29m |
| Dec 31 2018 | US$2m | US$579k | US$29m |
Compensation vs Market: Simon's total compensation ($USD2.81M) is above average for companies of similar size in the German market ($USD1.44M).
Compensation vs Earnings: Simon's compensation has increased whilst the company is unprofitable.
CEO
Simon de Vries (65 yo)
16.2yrs
Tenure
US$2,809,000
Compensation
Dr. Sijmen De Vries, also known as Simon, M. D., M. B.A., has been the Chief Executive Officer of Pharming Group N. V. since November 03, 2008 and also serves as its Executive Director since October 13, 20...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 16.2yrs | US$2.81m | 2.13% € 13.7m | |
| Chief Financial Officer | 4.2yrs | no data | 0.064% € 407.3k | |
| Chief Operations Officer | 5.4yrs | no data | 0.12% € 755.5k | |
| Investor Relations Manager | no data | no data | no data | |
| Chief Ethics & Compliance Officer | 3.7yrs | no data | 0.024% € 156.2k | |
| Chief People Officer | less than a year | no data | no data | |
| Chief Medical Officer | 3.6yrs | no data | 0.027% € 174.2k | |
| Chief Commercial Officer & GM Americas | 8yrs | no data | 0.028% € 177.5k | |
| Chief Business Officer | 1.3yrs | no data | 0.0096% € 61.8k | |
| Consultant | 3.6yrs | no data | no data |
3.7yrs
Average Tenure
58yo
Average Age
Experienced Management: PHGN's management team is considered experienced (3.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 16.3yrs | US$2.81m | 2.13% € 13.7m | |
| Independent Non-Executive Director | 3.7yrs | US$90.00k | 0.018% € 114.6k | |
| Independent Non-Executive Director | 4.1yrs | US$87.00k | 0.022% € 138.1k | |
| Independent Non-Executive Vice-Chairperson | 5.7yrs | US$87.00k | 0.024% € 152.8k | |
| Independent Non-Executive Director | 3.7yrs | US$90.00k | 0.018% € 114.6k | |
| Independent Non-Executive Director | 4.1yrs | US$94.00k | 0.022% € 138.1k | |
| Non-Executive Chairman of Board | 1.3yrs | US$46.00k | 0.0093% € 59.5k | |
| Independent Non-Executive Director | 3.7yrs | US$94.00k | 0.018% € 114.6k |
3.9yrs
Average Tenure
63yo
Average Age
Experienced Board: PHGN's board of directors are considered experienced (3.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 01:45 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pharming Group N.V. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Savin | Edison Investment Research |
| Simon Scholes | First Berlin Equity Research GmbH |
| Joseph Pantginis | H.C. Wainwright & Co. |